Cefuroxime_axetil has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


cefuroxime_axetil studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
CAE40408 IV An open-label study of sequential therapy with intravenous cefuroxime followed by oral cefuroxime axetil for the treatment of community acquired pneumonia (CAP)
CAE10004 I A study to determine the bioequivalence of reformulated 125mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 125mg/5mL suspension at a dose of 250mg.
CAE10005 I A study to determine the bioequivalence of reformulated 250mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 250mg/5mL suspension.